Coegin Pharma AB (NGM:COEGIN)
Sweden · Delayed Price · Currency is SEK 3.450
-0.020 (-0.58%)
At close: Jun 18, 2026
Coegin Pharma AB Company Description
Coegin Pharma AB, a biotechnology company, develops and commercializes cosmetic technologies for hair and skin in Sweden.
Its flagship product is Follicopeptide, a patented, clinically developed peptide technology targeting hair thinning; and NPP-4, a cosmetic peptide product designed to enhance skin tone without UV exposure or chemicals.
The company also develops FOL026, a peptide drug candidate for the treatment of myocardial infarction; AVX420, a drug candidate for the treatment of leukemia; and AVX001, a drug candidate for the topical treatment of both actinic keratosis and basal cell carcinoma.
Coegin Pharma AB was founded in 2005 and is headquartered in Lund, Sweden.
Coegin Pharma AB
| Country | Sweden |
| Founded | 2005 |
| Industry | Pharmaceutical Preparations |
| Employees | 3 |
| CEO | Jens Eriksson |
Contact Details
Address: Medicon Village Lund, 223 81 Sweden | |
| Phone | 46 72 221 24 21 |
| Website | coeginpharma.com |
Stock Details
| Ticker Symbol | COEGIN |
| Exchange | Nordic Growth Market |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jens Eriksson | Chief Executive Officer |
| Lars Rasmussen | Chief Financial Officer |